Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.

The company says the new device was designed to improve image quality, provide additional maneuverability and simplify ablation workflows for electrophysiologists. 

The company told Cardiovascular Business it respectfully disagrees with the jury's decision and is evaluating all possible legal options going forward. The Association of Medical Device Reprocessors, meanwhile, celebrated the news.

Patients often develop AFib during cardiac surgery, leading to longer hospital stays, additional healthcare costs and a higher risk of mortality. Cooling the oblique sinus of the patient's heart as soon as AFib starts to develop may represent a new way to stop the problem in its tracks. 

Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures. 

The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.

The newly approved device can be worn for up to a week at a time, with no daily maintenance required, and includes advanced AI algorithms that minimize the risk of false alarms or inappropriate shocks.